Scios developed and markets Natrecor® (nesiritide), the first new treatment for acute heart failure in more than a decade. Scios has a growing pipeline, including SCIO-469 and SCIO-323, of oral p38 kinase inhibitors in clinical trials. SCIO-469 is being studied for the potential treatment of rheumatoid arthritis (RA). Scios’ disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to design small molecule compounds for large markets with unmet medical needs. Scios also is advancing small-molecule inhibitors of TGF-beta through preclinical development. Scios' research effort is focused on diseases of the cardiovascular system, with a particular emphasis on inflammation and scarring. Scios has emphasized an emerging family of protein therapeutic targets: kinases. By applying advanced technologies with proprietary methodology, Scios is working to identify kinases active in diseases within its strategic focus and developing and testing inhibitors of those enzymes for potential therapeutic value. SCIO-469 and the emerging TGF-beta program represent the success of this innovative approach.